



## Bedeutung thrombophiler Risikofaktoren für das Erst- und Rezidivthromboserisiko

- 1) Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. *Thromb.Haemost.* 1995;74:449-453.
- 2) Rosendaal FR. Risk factors for venous thrombosis: Prevalence, risk, and interaction. *Seminars in Hematology* 1997;34:171-187.
- 3) Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High-Risk of Thrombosis in Patients Homozygous for Factor-V Leiden (Activated Protein-C Resistance). *Blood* 1995;85:1504-1508.
- 4) Emmerich J, Rosendaal FR, Cattaneo M et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. *Thromb.Haemost.* 2001;86:809-816.
- 5) Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. *Blood* 1996;88:3698-3703.
- 6) Junker R, Nowak-Göttl. The prothrombin G20210A mutation - a common cause of thrombophilia? *J.Lab.Med.* 1998
- 7) Ferraresi P, Marchetti G, Legnani C et al. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. *Arterioscler.Thromb.Vasc.Biol.* 1997;17:2418-2422.
- 8) Corral J, Gonzalez-Conejero R, Lozano ML et al. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. *Br.J.Haematol.* 1997;99:304-307.
- 9) Kapur RK, Mills LA, Spitzer SG, Hultin MB. A prothrombin gene mutation is significantly associated with venous thrombosis. *Arteriosclerosis Thrombosis and Vascular Biology* 1997;17:2875-2879.
- 10) Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. *Thromb.Haemost.* 1997;78:1430-1433.
- 11) Hillarp A, Zoller B, Svensson PJ, Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. *Thromb.Haemost.* 1997;78:990-992.
- 12) Margaglione M, D'Andrea G, d'Addetta M et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV leiden and the prothrombin A(20210) mutation. *Thrombosis and Haemostasis* 1998;79:907-911.
- 13) Rosendaal FR. Venous thrombosis: a multicausal disease. *Lancet* 1999;353:1453-1457.
- 14) Koeleman BPC, Reitsma PH, Allaart CF, Bertina RM. Activated Protein-C Resistance As An Additional Risk Factor for Thrombosis in Protein C-Deficient Families. *Blood* 1994;84:1031-1035.
- 15) Tait RC, Walker ID, Perry DJ et al. Prevalence of Antithrombin Deficiency in the Healthy Population. *British Journal of Haematology* 1994;87:106-112.
- 16) Koster T, Rosendaal FR, Briet E et al. Protein-C Deficiency in A Controlled Series of Unselected Outpatients - An Infrequent But Clear Risk Factor for Venous Thrombosis (Leiden Thrombophilia Study). *Blood* 1995;85:2756-2761.
- 17) Faioni EM, Valsecchi C, Palla A et al. Free protein S deficiency is a risk factor for venous thrombosis. *Thrombosis and Haemostasis* 1997;78:1343-1346.
- 18) Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *Journal of Thrombosis and Haemostasis* 2006;4:295-306.
- 19) Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. *Blood* 2007;109:422-430.
- 20) Galli M. Antiphospholipid syndrome: Association between laboratory tests and clinical practice. *Pathophysiology of Haemostasis and Thrombosis* 2003;33:249-255.





- 21) Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. *Blood* 2003;101:1827-1832.
- 22) Ortel TL. Thrombosis and the Antiphospholipid Syndrome. *Hematology* 2005;462-468.
- 23) Cervera R, Piette JC, Font J et al. Antiphospholipid syndrome - Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. *Arthritis and Rheumatism* 2002;46:1019-1027.
- 24) Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period - A comparison of early and late manifestations in a cohort of 1,000 patients. *Medicine* 2003;82:299-308.
- 25) Levine JS, Branch DW, Rauch J. Medical progress: The antiphospholipid syndrome. *New England Journal of Medicine* 2002;346:752-763.
- 26) Zotz RB, Sucker C, Gerhardt A. Thrombophilia in pregnancy Venous thromboembolism, fetal loss, preeclampsia, intrauterine growth restriction. *Hamostaseologie* 2008;28:455-464.
- 27) Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008;133:844S-886S.
- 28) Zotz RB, Gerhardt A, Segendorf H, Scharf RE. Significance of hereditary risk factors in patients with spontaneous recurrent thromboembolism [abstract]. *Angiology* 2001;20:58-59.
- 29) Schulman S, Rhedin AS, Lindmarker P et al. A Comparison of 6 Weeks with 6 Months of Oral Anticoagulant-Therapy After A First Episode of Venous Thromboembolism. *New England Journal of Medicine* 1995;332:1661-1665.
- 30) Levine MN, Hirsh J, Gent M et al. Optimal Duration of Oral Anticoagulant-Therapy - A Randomized Trial Comparing 4 Weeks with 3 Months of Warfarin in Patients with Proximal Deep-Vein Thrombosis. *Thrombosis and Haemostasis* 1995;74:606-611.
- 31) Schulman S, Granqvist S, Holmstrom M et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. *New England Journal of Medicine* 1997;336:393-398.
- 32) Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. *New England Journal of Medicine* 1999;340:901-907.
- 33) Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. *New England Journal of Medicine* 2001;345:165-169.
- 34) Palareti G, Legnani C, Cosmi B et al. Risk of venous thromboembolism recurrence: High negative predictive value of D-dimer performed after oral anticoagulation is stopped. *Thrombosis and Haemostasis* 2002;87:7-12.
- 35) Agnelli G, Prandoni P, Becattini C et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. *Annals of Internal Medicine* 2003;139:19-25.
- 36) Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. *Lancet* 2003;362:523-526.
- 37) Palareti G, Legnani C, Cosmi B et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. *Circulation* 2003;108:313-318.
- 38) Kyrle PA, Minar E, Bialonczyk C et al. The risk of recurrent venous thromboembolism in men and women. *New England Journal of Medicine* 2004;350:2558-2563.
- 39) Sudlow MF, Campbell IA, Angel JH et al. Optimum Duration of Anticoagulation for Deep-Vein Thrombosis and Pulmonary-Embolism. *Lancet* 1992;340:873-876.
- 40) Prandoni P, Lensing AWA, Buller HR et al. Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer. *New England Journal of Medicine* 1992;327:1128-1133.
- 41) Pini M, Aiello S, Manotti C et al. Low-Molecular-Weight Heparin Versus Warfarin in the Prevention of Recurrences After Deep-Vein Thrombosis. *Thrombosis and Haemostasis* 1994;72:191-197.





- 42) Pinede L, Ninet J, Duhaut P et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. *Circulation* 2001;103:2453-2460.
- 43) Ridker PM, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. *New England Journal of Medicine* 2003;348:1425-1434.
- 44) Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism - A population-based cohort study. *Archives of Internal Medicine* 2000;160:761-768.
- 45) Spiezia L, Bernardi E, Tormene D et al. Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. *Thrombosis and Haemostasis* 2003;90:964-966.
- 46) Palareti G, Legnani C, Lee A et al. A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. *Thrombosis and Haemostasis* 2000;84:805-810.
- 47) Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism - A population-based case-control study. *Archives of Internal Medicine* 2000;160:809-815.
- 48) Prandoni P, Lensing AWA, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood* 2002;100:3484-3488.
- 49) vandenBelt AGM, Sanson BJ, Simioni P et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. *Archives of Internal Medicine* 1997;157:2227-2232.
- 50) Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. *New England Journal of Medicine* 2003;349:1133-1138.
- 51) Simioni P, Prandoni P, Lensing AWA et al. The risk of recurrent venous thromboembolism in patients with an Arg(506)->Gln mutation in the gene for factor V (factor V Leiden). *New England Journal of Medicine* 1997;336:399-403.
- 52) Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. *New England Journal of Medicine* 2000;343:457-462.
- 53) Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. *American Journal of Medicine* 1998;104:332-338.
- 54) Khamashta MA, Cuadrado MJ, Mujic F et al. The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome. *New England Journal of Medicine* 1995;332:993-997.
- 55) Prandoni P, Lensing AWA, Prins MH et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. *Annals of Internal Medicine* 2002;137:955-960.
- 56) Eichinger S, Minar E, Bialonczyk C et al. D-dimer levels and risk of recurrent venous thromboembolism. *Jama-Journal of the American Medical Association* 2003;290:1071-1074.
- 57) De Stefano V, Martinelli I, Mannucci PM et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. *New England Journal of Medicine* 1999;341:801-806.
- 58) Piovella F, Crippa L, Barone M et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with DVT recurrence and new thrombosis. *Haematologica* 2002;87:515-522.
- 59) Kearon C, Ginsberg JS, Kovacs MJ et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. *New England Journal of Medicine* 2003;349:631-639.
- 60) Lindmarker P, Schulman S. The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. *Journal of Internal Medicine* 2000;247:601-606.
- 61) Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism - A meta-analysis. *Annals of Internal Medicine* 2003;139:893-900.
- 62) Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment. *Chest* 2004;126:287S-310S.





- 63) Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *American Journal of Medicine* 1998;105:91-99.
- 64) Hull R, Hirsh J, Jay R et al. Different Intensities of Oral Anticoagulant-Therapy in the Treatment of Proximal-Vein Thrombosis. *New England Journal of Medicine* 1982;307:1676-1681.
- 65) Turpie AG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. *Lancet* 1988;1:1242-1245.
- 66) Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. *N.Engl.J.Med.* 1990;322:428-432.
- 67) Altman R, Rouvier J, Gurfinkel E et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. *J.Thorac.Cardiovasc.Surg.* 1991;101:427-431.
- 68) A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. *Ann.Neurol.* 1997;42:857-865.
- 69) Cannegieter SC, Rosendaal FR, Wintzen AR et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. *N.Engl.J.Med.* 1995;333:11-17.
- 70) Hylek EM, Singer DE. Risk-Factors For Intracranial Hemorrhage in Outpatients Taking Warfarin. *Annals of Internal Medicine* 1994;120:897-902.
- 71) Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. *Lancet* 1996;348:633-638.
- 72) Fihn SD, McDonnell M, Martin D et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. *Ann.Intern.Med.* 1993;118:511-520.
- 73) Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin - A randomized, controlled trial. *Annals of Internal Medicine* 2000;133:687-695.
- 74) Fuster V, Califf RM, Chesebro JH et al. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. *Lancet* 1997;350:389-396.
- 75) Meade TW, Wilkes HC, Kelleher CC et al. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. *Lancet* 1998;351:233-241.
- 76) Fiore LD, Ezekowitz MD, Brophy MT et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. *Circulation* 2002;105:557-563.
- 77) Johnsen SP, Sorensen HT, Mellekjoer L et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. *Thromb.Haemost.* 2001;86:563-568.
- 78) Knijff-Dutmer EA, Schut GA, Van de Laar MA. Concomitant coumarin-NSAID therapy and risk for bleeding. *Ann.Pharmacother.* 2003;37:12-16.
- 79) Mellekjaer L, Blot WJ, Sorensen HT et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. *Br.J.Clin.Pharmacol.* 2002;53:173-181.
- 80) Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease. *Chest* 2008;133:454S-545S.
- 81) Seligsohn U, Lubetsky A. Medical progress: Genetic susceptibility to venous thrombosis. *New England Journal of Medicine* 2001;344:1222-1231.
- 82) Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of Clotting Factor-VIII in Effect of Von-Willebrand-Factor on Occurrence of Deep-Vein Thrombosis. *Lancet* 1995;345:152-155.
- 83) Wahl DG, Guillemin F, de Maistre E et al. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. *Lupus* 1998;7:15-22.





- 84) Oger E, Lacut K, Le Gal G et al. Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case-control study. *Journal of Thrombosis and Haemostasis* 2006;4:793-799.
- 85) Ridker PM, Miletich JP, Stampfer MJ et al. Factor-V Leiden and Risks of Recurrent Idiopathic Venous Thromboembolism. *Circulation* 1995;92:2800-2802.
- 86) Lindmarker P, Schulman S, Sten-Linder M et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. *Thrombosis and Haemostasis* 1999;81:684-689.
- 87) Eichinger S, Weltermann A, Mannhalter C et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. *Arch.Intern.Med.* 2002;162:2357-2360.
- 88) Segendorf H, Zotz RB, Gerhardt A, Pilch J, Scharf RE. Independent risk factor of recurrent venous thromboembolism in multivariate statistical analysis [abstract]. *Annals of Hematology* 2000;79:V201b.
- 89) Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. *N.Engl.J.Med.* 2000;342:374-380.
- 90) Mcrae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. *Lancet* 2006;368:371-378.
- 91) Kearon C. Long-term management of patients after venous thromboembolism. *Circulation* 2004;110:110-118.
- 92) Weltermann A, Eichinger S, Bialonczyk C et al. The risk of recurrent venous thromboembolism among patients with high factor IX levels. *Journal of Thrombosis and Haemostasis* 2003;1:28-32.
- 93) Palareti G, Tosetto A, Cosmi B et al. The D-dimer Test to establish the duration of anticoagulation after a first unprovoked episode of venous thrombosis (VTE): the prospective randomized "Prolong" study on behalf of the Italian Federation of Anticoagulant Clinics (FCSA). [abstract]. *Journal of Thrombosis and Haemostasis* 2005;3:H20.
- 94) Stain M, Schonauer V, Minar E et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. *J.Thromb.Haemost.* 2005;3:2671-2676.
- 95) Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis - Incidence and risk factors. *Archives of Internal Medicine* 2000;160:769-774.